Tikun Olam-Cannbit Pharmaceuticals Ltd
Tel Aviv Stock Exchange TKUN.TA
Tikun Olam-Cannbit Pharmaceuticals Ltd Return on Equity (ROE) for the year ending December 31, 2023: -217.47%
Tikun Olam-Cannbit Pharmaceuticals Ltd Return on Equity (ROE) is -217.47% for the year ending December 31, 2023, a -439.33% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.
-
Tikun Olam-Cannbit Pharmaceuticals Ltd Return on Equity (ROE) for the year ending December 31, 2022 was -40.32%, a -81.00% change year over year.
-
Tikun Olam-Cannbit Pharmaceuticals Ltd Return on Equity (ROE) for the year ending December 31, 2021 was -22.28%, a 6.73% change year over year.
-
Tikun Olam-Cannbit Pharmaceuticals Ltd Return on Equity (ROE) for the year ending December 31, 2020 was -23.89%, a -119.18% change year over year.
-
Tikun Olam-Cannbit Pharmaceuticals Ltd Return on Equity (ROE) for the year ending December 31, 2019 was -10.90%.
Key data
| Date | Return on Equity (ROE) | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio |
|---|
Market news
Loading...
Don’t Miss A Beat
Tel Aviv Stock Exchange: TKUN.TA
| CEO | Mr. Ronen Elad |
| IPO Date | Aug. 12, 2002 |
| Location | Israel |
| Headquarters | Hitad 2 |
| Employees | 50 |
| Sector | Health Care |
| Industries | |
Description
Tikun Olam-Cannbit Pharmaceuticals Ltd engages in the research, development, cultivation, manufacture, and distribution of medical cannabis and related products. It also provides training and patient care services. The company is based in Nof Hagalil, Israel.
Key trends
Past 5 years
StockViz Staff
January 29, 2025
Any question? Send us an email